Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis | Synapse

May 3, 2007Open Access

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Black et al. (Thu,) studied this question.

synapsesocial.com/papers/69d92136e6ab964fb08358f5 https://doi.org/https://doi.org/10.1056/nejmoa067312

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy2006 · 134 citations
2Bisphosphonates and Ocular Inflammation2003 · 124 citations
3Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis1996 · 1,013 citations
4Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study2004 · 279 citations
5Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study2005 · 329 citations